Cargando…
“Model T” Cells: A Time-Tested Vehicle for Gene Therapy
T lymphocytes first carried foreign genes safely into humans over two decades ago. Since these pioneering studies, scientific techniques to better understand the genomic landscape of cells has directly led to a more sophisticated appreciation of the diversity, functional complexity, and therapeutic...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784795/ https://www.ncbi.nlm.nih.gov/pubmed/24098300 http://dx.doi.org/10.3389/fimmu.2013.00304 |
_version_ | 1782477597897129984 |
---|---|
author | Kerkar, Sid P. |
author_facet | Kerkar, Sid P. |
author_sort | Kerkar, Sid P. |
collection | PubMed |
description | T lymphocytes first carried foreign genes safely into humans over two decades ago. Since these pioneering studies, scientific techniques to better understand the genomic landscape of cells has directly led to a more sophisticated appreciation of the diversity, functional complexity, and therapeutic potential of T cells. Through the use of mouse models, we now know the function of the many genes that are critical for T cells to recognize foreign, mutated, or self-antigens and the factors responsible for the lineage diversification of T cells that lead to inhibitory or stimulatory immune responses. This knowledge combined with well-established modalities to introduce genes into T cells allows for the design of effector and memory CD8 and CD4 T lymphocytes specific for viral, fungal, bacterial, parasitic, and tumor-antigens and to design regulatory lymphocytes specific for the self-antigens responsible for autoimmune and inflammatory diseases. Here, I review strategies for designing the ideal T cell by introducing genes controlling (1) the secretion of cytokines/chemokines and their receptors, (2) T-cell receptor specificity, (3) chimeric-antigen receptors that enable for the recognition of surface antigens in an MHC-independent fashion, (4) co-stimulatory/inhibitory surface molecules, and (5) disease defining single-gene factors. |
format | Online Article Text |
id | pubmed-3784795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-37847952013-10-04 “Model T” Cells: A Time-Tested Vehicle for Gene Therapy Kerkar, Sid P. Front Immunol Immunology T lymphocytes first carried foreign genes safely into humans over two decades ago. Since these pioneering studies, scientific techniques to better understand the genomic landscape of cells has directly led to a more sophisticated appreciation of the diversity, functional complexity, and therapeutic potential of T cells. Through the use of mouse models, we now know the function of the many genes that are critical for T cells to recognize foreign, mutated, or self-antigens and the factors responsible for the lineage diversification of T cells that lead to inhibitory or stimulatory immune responses. This knowledge combined with well-established modalities to introduce genes into T cells allows for the design of effector and memory CD8 and CD4 T lymphocytes specific for viral, fungal, bacterial, parasitic, and tumor-antigens and to design regulatory lymphocytes specific for the self-antigens responsible for autoimmune and inflammatory diseases. Here, I review strategies for designing the ideal T cell by introducing genes controlling (1) the secretion of cytokines/chemokines and their receptors, (2) T-cell receptor specificity, (3) chimeric-antigen receptors that enable for the recognition of surface antigens in an MHC-independent fashion, (4) co-stimulatory/inhibitory surface molecules, and (5) disease defining single-gene factors. Frontiers Media S.A. 2013-09-27 /pmc/articles/PMC3784795/ /pubmed/24098300 http://dx.doi.org/10.3389/fimmu.2013.00304 Text en Copyright © 2013 Kerkar. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Kerkar, Sid P. “Model T” Cells: A Time-Tested Vehicle for Gene Therapy |
title | “Model T” Cells: A Time-Tested Vehicle for Gene Therapy |
title_full | “Model T” Cells: A Time-Tested Vehicle for Gene Therapy |
title_fullStr | “Model T” Cells: A Time-Tested Vehicle for Gene Therapy |
title_full_unstemmed | “Model T” Cells: A Time-Tested Vehicle for Gene Therapy |
title_short | “Model T” Cells: A Time-Tested Vehicle for Gene Therapy |
title_sort | “model t” cells: a time-tested vehicle for gene therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784795/ https://www.ncbi.nlm.nih.gov/pubmed/24098300 http://dx.doi.org/10.3389/fimmu.2013.00304 |
work_keys_str_mv | AT kerkarsidp modeltcellsatimetestedvehicleforgenetherapy |